DE102008012909A1 - Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen - Google Patents

Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen Download PDF

Info

Publication number
DE102008012909A1
DE102008012909A1 DE102008012909A DE102008012909A DE102008012909A1 DE 102008012909 A1 DE102008012909 A1 DE 102008012909A1 DE 102008012909 A DE102008012909 A DE 102008012909A DE 102008012909 A DE102008012909 A DE 102008012909A DE 102008012909 A1 DE102008012909 A1 DE 102008012909A1
Authority
DE
Germany
Prior art keywords
glucuronide
quercetin
heart
extract
kaempferol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE102008012909A
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE102008012909A priority Critical patent/DE102008012909A1/de
Priority to PCT/EP2009/052502 priority patent/WO2009109573A1/de
Priority to JP2010549125A priority patent/JP2011527984A/ja
Priority to EP09718237A priority patent/EP2268277A1/de
Priority to CA2717012A priority patent/CA2717012A1/en
Priority to US12/919,561 priority patent/US20110053874A1/en
Publication of DE102008012909A1 publication Critical patent/DE102008012909A1/de
Priority to US13/710,799 priority patent/US20130109641A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DE102008012909A 2008-03-06 2008-03-06 Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen Withdrawn DE102008012909A1 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
DE102008012909A DE102008012909A1 (de) 2008-03-06 2008-03-06 Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen
PCT/EP2009/052502 WO2009109573A1 (de) 2008-03-06 2009-03-03 Verwendung von flavonoidverbindungen für die propyhylaxe und therapie ischämischer oder entzündlicher herz- und kreislauferkrankungen
JP2010549125A JP2011527984A (ja) 2008-03-06 2009-03-03 虚血性又は炎症性の心疾患及び心臓血管疾患の予防と治療のためのフラボノイド化合物の使用
EP09718237A EP2268277A1 (de) 2008-03-06 2009-03-03 Verwendung von flavonoidverbindungen für die propyhylaxe und therapie ischämischer oder entzündlicher herz- und kreislauferkrankungen
CA2717012A CA2717012A1 (en) 2008-03-06 2009-03-03 Use of flavonoide compounds for the propyhylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases
US12/919,561 US20110053874A1 (en) 2008-03-06 2009-03-03 Use of flavonoide compounds for the prophylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases
US13/710,799 US20130109641A1 (en) 2008-03-06 2012-12-11 Use of flavonoide compounds for the prophylaxis and therapy of ischaemic or inflammatory heart and cardiovascular diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008012909A DE102008012909A1 (de) 2008-03-06 2008-03-06 Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen

Publications (1)

Publication Number Publication Date
DE102008012909A1 true DE102008012909A1 (de) 2009-09-10

Family

ID=40600026

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102008012909A Withdrawn DE102008012909A1 (de) 2008-03-06 2008-03-06 Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen

Country Status (6)

Country Link
US (2) US20110053874A1 (enExample)
EP (1) EP2268277A1 (enExample)
JP (1) JP2011527984A (enExample)
CA (1) CA2717012A1 (enExample)
DE (1) DE102008012909A1 (enExample)
WO (1) WO2009109573A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110200539A1 (en) * 2007-08-31 2011-08-18 Boehringer Ingelheim International Gmbh Sprayable composition comprising extract of red vine leaves
DE102008012908A1 (de) * 2008-03-06 2009-09-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Methode zum anti-inflammatorischen und anti-ödematösen Schutz von explantiertem biologischen Material bis zu seiner Transplantation in Patienten
KR102169002B1 (ko) 2012-10-11 2020-10-23 아르마론 바이오 피티와이 리미티드 신규 플라보이드 화합물 및 이들의 용도
CN113398114B (zh) * 2021-05-28 2022-11-01 浙江大学智能创新药物研究院 3,7,8,4′-四羟基黄酮在制备抗心血管疾病药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1225810A1 (en) 1999-10-20 2002-07-31 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Method for treatment of chronic venous insufficiencies using an extract of red vine leaves
EP1581195A1 (en) 2002-12-31 2005-10-05 Boehringer Ingelheim International GmbH Film coated tablet comprising an extract of red vine leaves

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2348395C (en) * 1998-10-29 2009-12-22 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions comprising a mixture of bioflavonols
DE60118759T2 (de) * 2000-05-25 2006-09-14 Boehringer Ingelheim International Gmbh Zusammensetzung zum verbesserten zellenschutz welche ein lipophiles antioxidans sowie ein hydrophilen antioxidans enthält
CN1197567C (zh) * 2002-10-21 2005-04-20 中国人民解放军第二军医大学 山奈酚衍生物用于制备防治脑血管疾病药物的用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1225810A1 (en) 1999-10-20 2002-07-31 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Method for treatment of chronic venous insufficiencies using an extract of red vine leaves
EP1581195A1 (en) 2002-12-31 2005-10-05 Boehringer Ingelheim International GmbH Film coated tablet comprising an extract of red vine leaves

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Brunnet et al., Cochrane Database of Systematic Reviews 2005, Issue 4. Art. No.: CD002128
Feng et al., Lancet 2006; 367: 320-326
Formica et al., Fd Chem. Toxic 1995; 12: 1061-1080
Graefe et al., Journal of Clinical Pharmacology 2001; 41 (5): 492-499
Knekt et al., BMJ 1996; 312: 478-481
Kroon et al. Am J Clin Nutr 2004; 80: 15-21
Manach et al. Am J Clin Nutr 2005; 81 (1 Suppl): 230S-242S
McAnlis et al., Eur J Clin Nutr 1999; 53 (2): 92-96
Yusuf et al., Lancet 2004; 364 (9438): 937-952

Also Published As

Publication number Publication date
WO2009109573A1 (de) 2009-09-11
EP2268277A1 (de) 2011-01-05
CA2717012A1 (en) 2009-09-11
US20110053874A1 (en) 2011-03-03
JP2011527984A (ja) 2011-11-10
US20130109641A1 (en) 2013-05-02

Similar Documents

Publication Publication Date Title
Mahi-Birjand et al. Protective effects of pharmacological agents against aminoglycoside-induced nephrotoxicity: A systematic review
DE60218443T2 (de) Jasmonate enthaltende therapeutische zusammensetzungen für die behandlung von krebs
CN107206040A (zh) 用于管理或改进骨病症、软骨病症或二者的组合物和方法
Kermanshah et al. Olive leaf and its various health-benefitting effects: A review study
Kimenju et al. In vitro anthelmintic potential of Vernonia amygdalina and Secamone africana on gastrointestinal nematodes
Albuquerque et al. Medicinal plants and animals of an important seasonal dry forest in Brazil.
Shaik Phytochemistry and pharmacological potential of Terminalia arjuna L.
Arya et al. Bioactive compounds and health benefits of jamun (Syzygium cumini)
EP3142671B1 (de) Kombination von biologisch aktiven substanzen zur behandlung von hyperglykämischen erkrankungen
DE102008012909A1 (de) Verwendung von Flavonoidverbindungen für die Prophylaxe und Therapie ischämischer oder entzündlicher Herz- und Kreislauferkrankungen
Eğilmez et al. The effect of Hypericum perforatum L.(St. John's Wort) on prevention of myringosclerosis after myringotomy in a rat model
Jujun et al. Acute and repeated dose 28-day oral toxicity study of Garcinia mangostana Linn. rind extract
Khursheed et al. Phytochemical and pharmacological investigations on Adhatoda zeylanica (medic.): A review
EP2229950B1 (de) Verwendung von Pflanzen der Gattung Sideritis und Extrakten daraus zur Behandlung des Aufmerksamkeitsdefizit-Hyperaktivitätssyndroms
Mphaphathi et al. The Use of Plants Extracts during Cryopreservation of Livestock Epididymal Semen
RU2342942C1 (ru) Средство растительного происхождения, обладающее антиоксидантной активностью
Chikaraddy et al. Hypoglycemic activity of ethanolic extract of Lawsonia inermis linn.(henna) in alloxan-induced diabetic albino rats
Basiru et al. Effects of aqueous leaves extract of Waltheria indica Linn on reproductive indices of male albino rats
Kawade et al. A pharmacognostic and pharmacological review: Amaranthus spinosus
Thema et al. Epididymal Semen
Ezekwesili et al. Ant diabetic Effects of Combinations (Ratios) Of Selected Nigerian Ant diabetic Plants
Kiessoun et al. In Vitro Antioxidant and Antiinflammatory Profiles of Bioactive Fraction From Opilia Celtidifolia (Guill. & Perr.) Endl. Ex Walp (Opiliaceae)
Hieu et al. Anti-bacterial and anti-diarrheal evaluation of Moringa oleifera
Moneim et al. Evaluation of thE thErapEutic potEntial of tamarind sEEds (aquEous Extract) vErsus antidiabEtic drugs on thE histological structurE of lingual papillaE in diabEtic rats
Ajegi et al. Evaluation of the antiulcer and antimicrobial activities of methanol leaf extract of Helianthus annuus

Legal Events

Date Code Title Description
8130 Withdrawal
8165 Publication of following application cancelled